VENUSREM vs WOCKPHARMA: Stock Comparison

Venus Remedies Limited vs Wockhardt Ltd

Live data: 12 June 2026, 4:08 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Venus Remedies Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Venus Remedies Limited and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, VENUSREM is more favourable on 10 of 13 scored metrics and WOCKPHARMA on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹2,270 Cr
P/E Ratio
VENUSREM has a lower P/E
20.57x vs 144.46x
P/B Ratio
VENUSREM has a lower P/B
3.6x vs 6.23x
EPS
VENUSREM has higher earnings per share
₹76.93 vs ₹13.1
Dividend Yield
VENUSREM has a higher dividend yield
0.56% vs 0%
Revenue Growth (TTM YoY)
VENUSREM has faster revenue growth
33% vs 26%
EPS Growth (TTM YoY)
VENUSREM has faster EPS growth
126.4% vs 0%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs 21.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricVENUSREMWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricVENUSREMWOCKPHARMA
Live Price₹1,797.5₹1,865.9
Day Change4.8%-1.6%
Volume2.46 L7.19 L
52-Week High₹1,800.8₹2,422.3
52-Week Low₹424₹1,086.7
Distance from 52W High-0.18%-22.97%

Valuation

MetricVENUSREMWOCKPHARMA
Market Cap₹2,270 Cr₹30,362 Cr
P/E Ratio20.57x144.46x
P/B Ratio3.6x6.23x
EPS₹76.93₹13.1
Book Value₹444.63₹304
Dividend Yield0.56%0%

Growth

MetricVENUSREMWOCKPHARMA
Revenue Growth (TTM YoY)33%26%
EPS Growth (TTM YoY)126.4%0%
Qtr Sales Growth21.4%29.9%
Qtr Profit Growth687%688%

Profitability & Leverage

MetricVENUSREMWOCKPHARMA
ROE15.48%6.11%
ROCE11.1%7.55%
Net Margin13.35%3.3%
Operating Margin17.44%19.3%
Debt to Equity0x0.45x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricVENUSREMWOCKPHARMA
Promoter Holding41.76%49.08%
FII Holding2.92% 0.12 pp7.09% 0.1 pp
DII Holding0.89% 0.31 pp10.96% 0.41 pp
Public Holding54.43% 0.19 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Venus Remedies Limited and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.